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id-fast bacilli (Figure). We grew cul-
tures of acid-fast bacilli on trypticase 
soy agar after 2 to 4 days. The colo-
nies were nonchromogenic, smooth 
to mucoid, and off-white to cream 
on Middlebrook 7H10 and trypticase 
soy agar. 
We tested the in vitro antimicro-
bial susceptibility using the broth dilu-
tion method (7). The isolate suscepti-
ble to amikacin, cefoxitin, imipenem, 
doxycycline, and ciproﬂ  oxacin and re-
sistant to sulfamethoxazole, clarithro-
mycin, and tobramycin. We initiated 
treatment of the patient with moxi-
ﬂ   oxacin, minocycline, and amikacin 
1 day after the athroscopy and the pa-
tient’s fever subsided within 72 hours. 
We continued amikacin therapy for 1 
month and administered moxiﬂ  oxacin 
and minocycline for 6 months.
This patient is unique because she 
had a case of bacteremia caused by M. 
wolinskyi, and she had no history of 
major traumatic injury. The bacterium 
might have been introduced during im-
plantation of the venous port or during 
minor trauma that went unnoticed. The 
chemotherapeutic regimen adminis-
tered to our patient may have played a 
role in the infection. Immunosuppres-
sion by treatment with rituximab (an 
anti-CD20 monoclonal antibody) and 
a steroid during chemotherapy may 
have worsened the patient’s B-cell 
function and thereby weakened her 
immunity. Surgical debridement fol-
lowed by antimicrobial therapy for at 
least 6 months is the suggested treat-
ment for M. wolinskyi infection, and 
we followed this regimen. Because 
of the frequency of relapse and resis-
tance, we used combination therapy 
with multiple antimicrobial agents. 
This case suggests that immuno-
compromised patients may be vulner-
able to infection by rapidly growing 
mycobacterium such as M. wolinskyi. 
In such cases, we suggest antimicrobial 
drug treatment, based on in vitro sus-
ceptibility. More data on antimicrobial 
drug susceptibility should be collected 
for treatment of this type of infection.
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Incubation Period 
for Human Cases of 
Avian Inﬂ  uenza A 
(H5N1) Infection, 
China 
To the Editor: Since 1997, more 
than 400 human cases of highly patho-
genic inﬂ  uenza A virus (H5N1) infec-
tion have been reported worldwide, 
including 30 from mainland China. 
Ascertainment of the incubation pe-
riod for inﬂ   uenza virus (H5N1) is 
important to deﬁ  ne exposure periods 
for surveillance of patients with sus-
pected inﬂ  uenza virus (H5N1) infec-
tion. Limited data on the incubation 
period suggest that illness onset oc-
curs <7 days after the last exposure to 
sick or dead poultry (1–4). For clus-
ters in which limited human-to-human 
virus transmission likely occurred, 
the incubation period appeared to be 
3–5 days (5–7) but was estimated to 
be 8–9 days in 1 cluster (5). In China, 
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exposure to sick or dead poultry in 
rural areas and visiting a live poultry 
market in urban areas were identiﬁ  ed 
as sources of inﬂ  uenza A virus (H5N1) 
exposures (8), but the incubation pe-
riod after such exposures has not been 
well described. 
We conducted a retrospective de-
scriptive study of 24 of 30 inﬂ  uenza 
virus (H5N1)  cases in China to estimate 
and compare incubation periods for 
different exposure settings, including 
case-patients exposed only to sick or 
dead poultry versus those exposed only 
to a wet poultry market, where small 
animals and poultry may be purchased 
live or slaughtered (see www.searo.
who.int/en/Section23/Section1001/
Section1110_11528.htm). Exposures 
may be direct (e.g., touching poultry) 
or indirect (e.g., no physical contact, 
but in close proximity to poultry, 
poultry products, or poultry feces). 
We excluded 6 cases, including 2 with 
unavailable epidemiologic data, 1 
without an identiﬁ  ed exposure source, 
2 in a cluster with limited person-
to-person transmission (6), and 1 in 
which the patient was exposed to both 
a wet poultry market and to sick or 
dead poultry. Epidemiologic data were 
collected through patients and family 
interviews and a review of case-pa-
tients’ medical records. 
The incubation period was de-
ﬁ   ned as the time from exposure to 
symptom onset. The maximum time 
from  ﬁ   rst exposure to illness onset 
was limited to 14 days for biological 
plausibility. For case-patients with 
exposures on multiple days, we cal-
culated each case-patient’s median 
incubation period and then calculated 
the overall median and range of the 
distribution of these median incuba-
tion periods. Similarly, the minimum 
and maximum incubation periods for 
case-patients with exposures on mul-
tiple days was estimated by using 
the last or ﬁ  rst known exposure day, 
respectively. The overall incubation 
period among these case-patients was 
estimated by determining the median 
of the distribution of case-patients’ 
median incubation periods. Incubation 
periods were compared by using the 
Wilcoxon rank-sum test. All statistical 
tests were 2-sided with a signiﬁ  cance 
level of α = 0.05. 
Of the 24 case-patients, 16 (67%) 
had exposure to sick or dead poultry 
only (median age = 25 years [range 
6–44]; 25% male; 100% lived in rural 
areas). Eight (33%) had visited a wet 
poultry market only (median age = 30 
years [range 16–41]; 63% male; 88% 
[7/8] lived in urban areas) (Table). For 
case-patients with >2 exposure days 
(n = 18), and for case-patients with a 
single exposure day (n = 6), the overall 
median incubation period was longer 
for those who had visited a wet poultry 
market than for those who were ex-
posed to sick or dead poultry, but the 
difference was not signiﬁ  cant. When 
data for single and multiple exposure 
days were combined, the overall medi-
an incubation period for case-patients 
exposed to a wet poultry market (n = 8) 
was signiﬁ  cantly longer than for case-
patients (n = 16) exposed to sick or 
dead poultry (7 days [range 3.5–9] vs. 
4.3 days [range 2–9]; p = 0.045). 
Our ﬁ  ndings are subject to limi-
tations. Proxies for deceased case-pa-
tients may not have known all of the 
case-patient’s exposures. Surviving 
case-patients may not have recalled or 
identiﬁ  ed all exposures that occurred, 
including environmental exposures. 
It was impossible to ascertain when 
infection occurred for case-patients 
with multiple days of exposures. Our 
limited data did not permit the use of 
other methods such as survival analy-
sis to better deﬁ  ne incubation periods. 
We did not quantify exposure dura-
tion and could not determine whether 
repeated exposures (dose-response) 
or a threshold of exposure to inﬂ  u-
enza A virus (H5N1) exists to initi-
ate infection of the respiratory tract. 
Laboratory testing was not performed 
to conﬁ  rm that the exposure sources 
contained inﬂ  uenza virus (H5N1) or 
to quantify exposures. 
Despite exposures of many per-
sons in China to sick or dead poultry 
or to wet poultry markets, human in-
ﬂ   uenza A (H5N1) disease remains 
very rare. Our ﬁ  ndings suggest that the 
incubation period may be longer after 
exposure to a wet poultry market than 
after exposure to sick or dead poultry, 
and, therefore, a longer incubation 
period than the 7 days that is used 
widely (4,9) could be considered for 
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Table. Estimated incubation period of 24 human cases of infection with avian influenza A virus (H5N1), China*  
Exposure data 
Case-patients with 
exposure to sick/ 
dead poultry only 
Case-patients with 
exposure to wet 
poultry market only  p value 
All case-
patients
No. case-patients with exposures on multiple days   12 6 18
  Overall median incubation period, d (range)  4.5 (2–9.5)  6.3 (3.5–7)  0.276 5 (2–9.5) 
  Median of minimum incubation period, d (range)  1 (0–5)  0 (0–2)  0.315 0.5 (0–5) 
  Median of maximum incubation period, d (range) 7.5 (4–14)  11.5 (7–14)  0.108 8.5 (4–14) 
No. case-patients with single known exposure   4 2 6
  Overall median incubation period, d (range)  3.5 (2–6)  8.5 (8–9)  0.064 5 (2–9) 
All case-patients  16 8 24
  Overall median incubation period, d (range)  4.3 (2–9)  7 (3.5–9)  0.045 5 (2–9.5) 
  Overall median of minimum incubation period, d (range)  1.5 (0–6)  1 (0–9)  0.752 1.5 (0–9) 
  Overall median of maximum incubation period, d (range)  6 (2–14)  9 (7–14)  0.031 7.5 (2–14) 
*Boldface represents significant results (Wilcoxon rank-sum test). LETTERS
surveillance purposes. However, be-
cause of the small number of inﬂ  uenza 
virus (H5N1) case-patients, our study 
was too underpowered to draw any 
ﬁ   rm conclusions; results should be 
interpreted cautiously. In a study of   
cases in Vietnam, 5 case-patients did 
not have any identiﬁ  ed exposure <7 
days of illness onset (10). In China, 
the exposure period for surveillance 
of suspected cases now includes ex-
posure to a wet poultry market <14 
days before illness onset. Although 
data on person-to-person virus trans-
mission are limited, close contacts 
of patients infected with inﬂ  uenza 
virus (H5N1) in China are monitored 
daily for 10 days after the last known 
exposure. Further studies are needed to 
quantify the incubation period after ex-
posure to sick or dead infected poultry, 
a wet poultry market, or to an inﬂ  uenza 
A virus (H5N1) case-patient and to in-
vestigate the basis for any differences. 
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Mycobacterium 
haemophilum 
Infection after 
Alemtuzumab 
Treatment
To the Editor: The immuno-
suppressive agent alemtuzumab is a 
DNA-derived, humanized monoclonal 
antibody directed against the panlym-
phocyte, cell-surface antigen CD52 (1). 
The drug is approved for the treatment 
of refractory B-cell chronic lympho-
cytic leukemia (2) and also has been 
used after stem cell (3) and organ trans-
plantations (4). Alemtuzumab causes 
profound and prolonged lymphocyte 
depletion, which results in a variety of 
complications involving infections (5). 
However, mycobacteria have rarely 
been reported to cause infection after 
alemtuzumab treatment. We describe 
infections with Mycobacterium hae-
mophilum, a fastidious nontuberculous 
mycobacterium, in 2 patients who ex-
perienced cutaneous lesions while they 
received alemtuzumab.
Patient 1
A 65-year-old man with refrac-
tory chronic lymphocytic leukemia 
had been receiving treatment with 
alemtuzumab for 3 months. During 
a 5-week period beginning 15 weeks 
after the alemtuzumab therapy started, 
20–30 tender nodular-ulcerative le-
sions developed on the patient’s ex-
tremities. Most of the lesions were 
distributed along a saphenous vein site 
(Figure). Immediately before receiv-
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